Research programme: gene therapies - Adverum Biotechnologies

Drug Profile

Research programme: gene therapies - Adverum Biotechnologies

Alternative Names: AAV.7m8-aflibercept; AAV.7m8-ranibizumab; ADVM 043; ADVM-022; ADVM-032; ANN 001; ANN-003; ANN-004

Latest Information Update: 20 Oct 2016

Price : $50

At a glance

  • Originator Weill Cornell Medical College
  • Developer Adverum Biotechnologies; Weill Cornell Medical College
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alpha 1-antitrypsin deficiency; Hypersensitivity; Wet age-related macular degeneration
  • Research Cardiomyopathies

Most Recent Events

  • 14 Oct 2016 Adverum Biotechnologies plans toxicological studies in Wet age-related macular degeneration ,
  • 14 Oct 2016 Adverum Biotechnologies plans to initiate enrolment in a phase I/II trial for Alpha-1 antitrypsin deficiency
  • 16 Sep 2016 Preclinical trials in Wet age-related macular degeneration in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top